A novel Pfs38 protein complex on the surface of Plasmodium falciparum blood-stage merozoites
© The Author(s) 2017
Received: 23 November 2016
Accepted: 28 January 2017
Published: 16 February 2017
The Plasmodium genome encodes for a number of 6-Cys proteins that contain a module of six cysteine residues forming three intramolecular disulphide bonds. These proteins have been well characterized at transmission as well as hepatic stages of the parasite life cycle. In the present study, a large complex of 6-Cys proteins: Pfs41, Pfs38 and Pfs12 and three other merozoite surface proteins: Glutamate-rich protein (GLURP), SERA5 and MSP-1 were identified on the Plasmodium falciparum merozoite surface.
Recombinant 6-cys proteins i.e. Pfs38, Pfs12, Pfs41 as well as PfMSP-165 were expressed and purified using Escherichia coli expression system and antibodies were raised against each of these proteins. These antibodies were used to immunoprecipitate the native proteins and their associated partners from parasite lysate. ELISA, Far western, surface plasmon resonance and glycerol density gradient fractionation were carried out to confirm the respective interactions. Furthermore, erythrocyte binding assay with 6-cys proteins were undertaken to find out their possible role in host-parasite infection and seropositivity was assessed using Indian and Liberian sera.
Immunoprecipitation of parasite-derived polypeptides, followed by LC–MS/MS analysis, identified a large Pfs38 complex comprising of 6-cys proteins: Pfs41, Pfs38, Pfs12 and other merozoite surface proteins: GLURP, SERA5 and MSP-1. The existence of such a complex was further corroborated by several protein–protein interaction tools, co-localization and co-sedimentation analysis. Pfs38 protein of Pfs38 complex binds to host red blood cells (RBCs) directly via glycophorin A as a receptor. Seroprevalence analysis showed that of the six antigens, prevalence varied from 40 to 99%, being generally highest for MSP-165 and GLURP proteins.
Together the data show the presence of a large Pfs38 protein-associated complex on the parasite surface which is involved in RBC binding. These results highlight the complex molecular interactions among the P. falciparum merozoite surface proteins and advocate the development of a multi-sub-unit malaria vaccine based on some of these protein complexes on merozoite surface.
KeywordsPlasmodium falciparum 6-cys proteins Glycophorin A MSP-165
Malaria is a worldwide health problem, with 250 million people at risk and an estimated 438,000 deaths each year . Despite introduction of effective drugs and vector control tools, elimination or even eradication of malaria remains a distant prospect. Development of an efficacious vaccine would be an important tool to combat malaria. Since morbidity and mortality is associated with asexual parasite forms , blood-stage antigens have been major targets for vaccine development efforts. Unfortunately, all attempts to develop a malaria vaccine based on surface proteins from the Plasmodium falciparum merozoite have so far failed [3–6] possibly due to insufficient understanding of the molecular architecture of the merozoite surface proteins and their organization on the merozoite surface.
Protein complexes are critical for host-pathogen interactions and for many of the biological processes involved in intercellular contacts . Two merozoite surface protein complexes have a well-documented role in the invasion of erythrocytes. These are the P. falciparum merozoite surface protein-1 complex and the apical membrane antigen 1/rhoptry neck (RON)-complex [8–13]. A family of proteins referred to as 6-Cys domain proteins have recently gained interest as vaccine candidate antigens because of their critical role for parasite growth in the infected hepatocyte and in the mosquito midgut [14, 15]. Ten members of the 6-Cys family have been described in Plasmodium species that infect primates, rodents or birds [16, 17]. These proteins contain modules of six conserved cysteine residues forming three intramolecular disulfide bonds between C1–C2, C3–C6 and C4–C5. The numbers of 6-Cys modules vary from two to seven while the length of interspersed sequences between these modules varies from 7 to 160 aa [16, 18, 19]. The repeat units found in these proteins show double domain characteristics and are termed A-and B-type domains . Several of the 6-Cys proteins are attached to the outer leaflet of the plasma membrane by GPI anchors, while a few are associated with the parasite surface through protein–protein interactions [17, 20].
Pbs36 and Pbs36p, the two members of 6-Cys protein family are located on the surface of Plasmodium berghei sporozoites  and knock-outs of the corresponding genes resulted in cessation of parasite development in infected hepatocytes [14, 21]. Accordingly, P. berghei Pbs36 and Pbs36p knock-out sporozoites failed to progress to the asexual blood stage in infected mice. Since, these mice were protected from a subsequent challenge infection with wild-type P. berghei, some have advocated that Pfs36 and Pfs36p knock-out parasites may be developed for an attenuated vaccine [21–23]. The two sexual-stage 6-Cys proteins, Pfs230 and Pfs48/45, are well-established candidates for a transmission blocking vaccine because of their critical role in parasite fertilization and growth in the mosquito midgut [24–28]. In comparison to the 6-Cys proteins of the hepatic and transmission stages, little is known about the 6-Cys proteins expressed during the asexual blood stages. Four members of P. falciparum 6-Cys family, Pfs92, Pfs41, Pfs38 and Pfs12, are expressed at the asexual blood stages. Among these proteins Pfs41 and Pfs12 form a heterodimer on the merozoite surface and Pfs92 interacts with factor H that is recruited by merozoites to evade the human complement system [20, 29, 30].
Here, the association of Pfs38, Pfs41 and Pfs12 with each other and with other merozoite surface proteins was investigated using biochemical and several protein–protein interaction tools. The existence of a Pfs38 protein complex on merozoite surface and its interaction with human red blood cells (RBCs) were also explored. The analysis of the seroreactivity of members of the Pfs38 merozoite surface complex show that these proteins are strongly recognized by naturally acquired antibodies from geographically distant areas, suggesting a functional role for this complex during the natural infection.
In vitro Plasmodium falciparum culture
Plasmodium falciparum strain 3D7 was cultured on human erythrocytes (4% haematocrit) in RPMI 1640 media (Invitrogen) supplemented with 10% O+human serum using standard protocol described by Trager and Jensen . Parasite cultures were synchronized by two consecutive sorbitol treatments 4 h apart following the protocol described by Lambros and Vanderberg .
Cloning of Pfs38, Pfs12 and Pfs41 and PfMSP-165, GLURP (R2, R1, R0), SERA5
Pfs38 gene encompassing aa 22–328 was codon optimized and synthesized from Genescript Inc, USA. The 6-Cys domain of Pfs38 (aa 153–328) was PCR amplified from the synthetic gene using the primer pair: forward 5′ GCCCATGGGATCCAAAAAGGTGCTGCGTATTCACATCTCTAACGG 3′ and reverse 5′ GCGTCGACCTCGAGAATTTCTTCGCGTTC 3′ and cloned in pGEMT vector (Promega corporation, USA). The fragment was sub-cloned in the pET 28b expression vector between NcoI and XhoI sites. Pfs41 gene encompassing aa 28–378 and Pfs12 gene encompassing aa 26–323 was codon-optimized and synthesized from Genescript Inc, USA and subsequently sub-cloned between NcoI/XhoI site of pET28b.
PfMSP-165 encompassing aa 1052–1664 was amplified by PCR from P. falciparum 3D7 cDNA using primer pair forward.
5′ GCGCGGCCGCATCCATGGGACAGT TATCATTTGATTTATA TAATAAA 3′ and reverse 5′ GCGTCGACCTCGAGTGCATCACATCCACCATTATTTTC 3′ and cloned in pGEMT vector (Promega corporation, USA). The fragment was sub-cloned in the pET 28b expression vector between NcoI and XhoI site. GLURP (R2, R1, R0 fragments) and SERA5 was cloned as described earlier [33, 34].
Expression and purification of recombinant proteins
The pET28b plasmids having Pfs38 and PfMsp-165 genes were transformed in BL21 cells, while plasmids having Pfs12 and Pfs41 fragments were transformed in Rosetta cells. Each culture was induced at 1 mM IPTG for 5 h at 37 °C. The cells were disrupted by sonication in Tris-buffer (0.05 M Tris pH 8.0 and 0.15 M NaCl) with 9-s pulses at 9-s intervals for ten times using mini probe. The soluble and insoluble fractions were separated by centrifugation and analysed by SDS-PAGE. The expressed proteins Pfs38, Pfs12 and Pfs41were found to be present in inclusion bodies, while PfMSP-165 was found to be expressed as soluble protein. To purify the recombinant proteins, each Escherichia coli culture was induced with 1 mM IPTG for 5 h at 37 °C. The cell pellet was suspended in 1/20 volume of lysis buffer (0.05 M Tris, pH 8.0, 0.15 M NaCl, 0.01 M DTT, 100 µg/mL lysozyme, 1 mM PMSF, 1% Triton X-100). For Pfs38, Pfs41 and Pfs12 purification, the cell suspension was sonicated and centrifuged at 12,000×g for 30 min at 4 °C. Pellets were washed four times with Tris-buffer without Triton X-100. The inclusion bodies thus obtained were resuspended in 8 M urea. The suspension was incubated for 30 min at room temperature and centrifuged at 12,000×g for 30 min at 4 °C. Supernatant containing solubilized protein was kept for binding with Ni+2-NTA+ resin for 1 h at 4 °C with constant shaking. After binding, suspension was packed in a purification column and the resin was washed four times with 8 M urea buffer containing 10 mM imidazole. Bound protein(s) was eluted in lysis buffer containing 8 M urea with different concentrations of imidazole. Eluted protein fractions were analysed on 10% SDS-PAGE. Fractions containing almost pure protein were pooled and refolded by gently diluting the protein 40-fold in refolding buffer (0.05 M Tris pH-8, 1 M Urea, 1 mM EDTA, 0.5 M arginine, 0.4 mM triton X, 1 mM reduced glutathione, 0.5 mM oxidized glutathione) with constant stirring at 4 °C for 24 h. The refolded proteins were concentrated and dialyzed against 0.05 M Tris pH-8, 0.15 M NaCl and stored at −80 °C.
For the purification of PfMSP-165, the cell suspension was sonicated and centrifuged at 12,000×g for 30 min at 4 °C and the supernatant was incubated with Ni+2-NTA+ resin for 1 h at 4 °C. After binding, suspension was packed in a purification column and the resin was washed four times with non-denaturing buffer, 0.05 M Tris pH-8, 0.3 M NaCl containing 10 mM imidazole. Bound protein(s) was eluted in 0.05 M Tris pH-8, 0.15 M NaCl buffer containing different concentrations of imidazole. Eluted protein fractions were analysed on 10% SDS-PAGE. Fractions containing almost pure proteins were pooled and dialyzed against 0.05 M Tris pH-8, 0.15 M NaCl. The expressed proteins were run in reduced and non-reduced conditions and confirmed by Western blot analysis with monoclonal Anti-His antibody (Sigma Aldrich, USA). GLURP (R2, R1, R0 fragments) and SERA5 were expressed and purified as described earlier [33, 34].
Generation of antibodies against Pfs38, Pfs12 and Pfs41, PfMSP-165, GLURP (R0, R1 and R2 fragment) and SERA-5
Antibodies against Pfs38, Pfs12 and Pfs41 and PfMSP-165 were raised in both mice and rabbit. The animals were housed and handled in accordance with the institutional and national guidelines. The Institutional Animal Ethical Committee at ICGEB, New Delhi, India, approved the animal use protocol described in the studies. The animals were bred under the guidelines of the authorizing committee. For the antibody generation, 5–6 weeks old female BALB/c mice were immunized with 25 μg of each protein: rPfs38, rPfs12 and rPfs41 and rPfMSP-165 emulsified in Freund’s complete adjuvant on day 0, followed by three boosts of proteins emulsified with Freund’s incomplete adjuvant on days 14, 28 and 42. The animals were bled for serum collection on day 49. For rabbit immunization, New Zealand white female rabbits were immunized with 200 μg of either of the following recombinant proteins: rPfs38, rPfs12 and rPfs41 and rPfMSP-165 emulsified in Freund’s complete adjuvant on day 0, followed by three boosts emulsified with Freund’s incomplete adjuvant on days 21, 42 and 63. The animals were bled for serum collection on day 70. Antibody titres in serum samples were quantified by enzyme-linked immunosorbent assay (ELISA). Antibodies against GLURP (R2, R1 and R0 fragments) and SERA5 were raised according to protocols described earlier [33, 34].
Immunoblot analysis of Plasmodium falciparum merozoites
Briefly, P. falciparum merozoites were harvested and lysed with SDS sample buffer and boiled at 98 °C for 15 min. After removing insoluble material by centrifugation (15,000×g for 15 min), the parasite lysate was run on SDS-PAGE and transferred to nitrocellulose membrane. The membranes were probed with rabbit anti-Pfs38 (1:1000) or anti-Pfs12 (1:1000) or anti-Pfs41(1:1000) antisera followed by goat anti-rabbit HRP conjugated secondary antibody (1:3000). The membranes were developed with DAB/H2O2 solution (Sigma Aldrich, USA).
Parasites in late schizont stage (44–46 hpi) were collected by saponin lysis and washed several times to remove RBC contamination. Lysates for immunoprecipitation were prepared in IP lysis buffer (250 mM Tris, 150 mM NaCl, 1 mMEDTA, 1% NP-40, 5% glycerol; pH 7.4). Protein-A Agarose were used to bind 20 µg of polyclonal anti-Pfs38 antibody or anti-PfMSP-165 antibody or anti-Pfs 12 or anti-Pfs41 antibody while Protein-A Agarose incubated with 20 µg of pre-immune antibody served as a control. After 12 h of incubation at 4 °C, each antibody bound protein-A Agarose was washed with PBS and incubated with parasite lysate (~1 mg per 10 μL of Agarose). After 12 h of incubation, protein-A Agarose beads were washed with wash buffer and bound proteins were eluted from the beads using the elution Buffer (Tris–Glycine pH 2.8). Proteins in the immunoprecipitated samples were digested by in-solution trypsin digestion method. Samples were brought to a final volume of 100 µL in 50 mM ammonium bicarbonate (Sigma) buffer to adjust the pH to 7.8, reduced with 10 mM DTT (final concentration) for 1 h at room temperature (RT) and alkylated with 40 mM iodoacetamide (Sigma Aldrich, USA) for 1 h at RT under dark conditions. Proteins were digested by the addition of Promega sequencing grade modified trypsin (V511A) at a ratio 1:50 (w/w) of trypsin:protein. For complete digestion, samples were placed in a water bath at 37 °C for 18 h. After digestion, extracted peptides were acidified to 0.1% formic acid and analysed by Orbitrap VelosPro mass spectrometer coupled with nano-LC 1000 (Thermofisher Scientific Inc, USA).
In vitro interaction between members of the Pfs38 complex was examined by ELISA, as described previously with minor modifications . Briefly, 96-well microtitre plates were coated overnight with 2 µg/mL of Pfs38 at 4 °C. After blocking the wells with 5% skimmed milk in PBS, recombinant GLURP R0, GLURP R1, GLURP R2, PfMSP-165, PfMSP-119, Pfs41, Pfs12 and SERA5 were added in increasing concentrations of 2, 5, 10, and 20 µg/ml and plates were incubated for 2 h. For the ELISA interaction of glycophorin A with Pfs38, 1 µg/mL of glycophorin A was coated in microtitre plates at 4 °C and after blocking, increasing concentrations of Pfs38 or GLURP R2 or PfMLH (non-specific protein) were added and plates were incubated for 2 h. For the inhibition assay, 2 µg/mL of Pfs38 was coated at 4 °C and after blocking, anti-Pfs38 antibodies were added in increasing concentration of 0.25, 0.5, 1 and 2 mg/mL and incubated for 30 mins. This was followed by incubation with glycophorin A protein at 20 µg/mL for 2 h. Bound proteins were detected through polyclonal antibody raised against the respective proteins for 1 h. Horseradish peroxidase (HRP)-conjugated anti-mouse or anti-rabbit antibodies (1:3000) were added in each well for 1 h and binding was quantified after adding the substrate of phenylenediaminedihydrochloride (Sigma Aldrich, USA) by measuring the resulting absorbance at 490 nm in an ELISA microplate reader. All the experiments were done in triplicate and mean ± SEM was calculated.
Far western assay was carried out according to the protocol described earlier . Briefly 1–5 µg of recombinant Pfs38, Pfs41, Pfs12, PfMSP-165, PfMSP-119, and a non-specific protein PfMLH were separated by SDS-PAGE and transferred to a membrane. The proteins on the membranes were denatured and renatured. These membranes were blocked with 5% skimmed milk and incubated with 2 µg/mL of purified interacting bait proteins, i.e., recombinant GLURP R2 or Pfs38 or SERA-5 in protein-binding buffer (100 mM NaCl, 20 mM Tris (pH 7.6), 0.5 mM EDTA, 10% glycerol, and 1 mM DTT) for 2 h at RT. Membranes were washed to remove the non-specific interactions and were incubated with rabbit anti-GLURP R2 (1:1000) or rabbit anti-Pfs38 (1:1000) or mouse anti-SERA5 antisera (1:500) overnight at 4 °C followed by incubation with goat anti rabbit IRDye 800CW (1:15,000) or goat anti mouse IRDye 800CW (1: 15,000) for 2 h at RT. Finally, the membranes were imaged with a LI-COR Odyssey FC instrument.
Surface plasmon resonance (SPR) analysis
SPR assays were performed on BIACORE 2000 instrument (GE Healthcare) at 37 °C, using HBS-EP buffer (general purpose buffer, degassed and ready to use 0.01 M HEPES pH 7.4, 0.15 M NaCl, 3 mM EDTA, 0.005% v/v Surfactant P20; GE Healthcare Lifesciences, USA). Recombinant GLURP R2 was immobilized up to 400 response units in a flow cell of CM5 sensor-chip (GE Healthcare Lifesciences, USA). For kinetic measurements, increasing concentrations of recombinant Pfs38 were injected over immobilized GLURP R2 as well as the reference flow cell, at a flow rate of 20 μL/min. The surfaces were regenerated with a pulse of 10 mM Glycine at pH 1.5 at the end of each injection cycle. Duplicate injections of the same concentration in each experiment were superimposable, demonstrating no loss of activity after surface regeneration. Reference-subtracted sensorgrams were analysed using the Biacore evaluation software 4.1.1 (GE Healthcare Lifescienes, USA). To determine the kinetic parameters of the interaction, binding responses in the steady-state region of the sensorgrams were plotted against analyte concentration and fitted to the standard 1:1 (Langmuir) bimolecular interaction with simultaneous fitting of ka and kd.
Glycerol density gradient centrifugation
Briefly, schizont-stage parasite were lysed in 0.5% Nonidet P-40/Hepes-buffered saline (10 mM Hepes at pH 7.0, 150 mM NaCl, 2 mM MgCl2, 10 mM KCl, 0.5 mM EDTA, and protease inhibitors). Lysate was cleared by centrifugation and 500 μL of lysate was layered on top of a 9-mL 5–45% step glycerol gradient. Gradients were centrifuged at 38,000 rpm for 18 h at 4 °C ina SW41 rotor (Beckman). Twenty fractions of 0.5 mL each were collected from each gradient and equal volumes of each fraction were mixed with loading dye. Protein samples were resolved by SDS/PAGE and analysed by Western blotting using anti-Pfs38, anti-Pfs12, anti-Pfs41, anti-GLURP R2, anti-PfMSP-165 and anti-SERA5 antibody. In-solution trypsin digestion of fraction 5 followed by LC–MS/MS analysis was done to confirm the protein.
Indirect immunofluorescence assay (IFA)
Confocal laser scanning IFAs were performed with P. falciparum asexual blood stages. Cell fixation, antibody incubation and imaging were performed by standard techniques and microscopic examination was performed using a A1 confocal microscope (Nikon Instruments Inc, USA). Images were analysed using Nikon NIS Elements v 4.0 software. Imaris image was created using the software IMARIS v 4.0.
Erythrocyte binding assay
Invasion inhibition assay
Anti-Pfs38 IgG and pre-immune IgG were added to highly synchronized schizont-stage cultures (2% haematocrit and 1% parasitaemia) at final concentration of 2, 5 and 10 mg/mL. The cultures were incubated for 40 h for schizont rupture and merozoite invasion. Parasitaemia was counted by flow cytometry. Percentage inhibition was calculated relative to the pre-immune sera. Bars indicate mean ± SEM of duplicate measurements.
ELISA analysis was performed to determine the seroreactivity of the proteins of the Pfs38 complex using sera from naturally infected malaria patients as described earlier . Sera from 28 P. falciparum malaria patients in India and 28 P. falciparum malaria patients in Liberia was used, while sera from 28 Danish volunteers was used as a negative control. For assessing the conformation of three refolded 6-cys proteins; i.e. Pfs38, Pfs12 and Pfs41 as well as PfMsp-165 these proteins were denatured with 8 M Urea and seroreactivity was tested using 28 Liberian sera samples.
Expression and purification of recombinant Pfs41, Pfs38, Pfs12 and PfMSP-165 proteins in Escherichia coli
Identification of Pfs38 protein complex at asexual blood stages
Identification of malarial proteins immunoprecipitated using anti-Pfs38 antibody by LC/MS–MS analysis
Name of protein
Sequence coverage (%)
Sequences of peptides identified
Glutamate rich protein (GLURP)
Merozoite surface protein 1 (MSP-1)
Serine repeat antigen 5 (SERA-5)
Identification of malarial proteins immunoprecipitated using anti-PfMSP-165 antibody by LC/MS–MS analysis
Name of protein
Sequence coverage (%)
Sequences of peptides identified
Merozoite surface protein 1 (MSP-1)
Serine repeat antigen 5 (SERA-5)
Protein–protein interaction analysis of Pfs38 with other merozoite surface proteins
Co-localization and co-sedimentation analysis confirm an association of Pfs38 with other 6-cys proteins, SERA5 and PfMSP-165 on the merozoite surface
Pfs38 binds to human erythrocytes
Recombinant Pfs38 showed a dose-dependent interaction with glycophorin A (Fig. 4c), while GLURP R2 from the same complex and PfMLH (non-specific protein) did not show interaction to glycophorin A. These results are in line with a recent finding where MSP-1 amino terminus region (Msp-183) was found to bind with glycophorin A of human RBC even in the presence of neuraminidase treatment . Furthermore anti-Pfs38 antibodies could inhibit the interaction between Pfs38 and glycophorin A by up to 70% at 2 mg/mL (see Additional file 12). Together, these results show that Pfs38 protein of the Pfs38 protein complex binds to human erythrocyte via glycophorin A. Based on the results of interactions studies among the proteins of Pfs38 protein complex and interaction of Pfs38 with RBC surface, a model is proposed for the organization of Pfs38 protein complex (Fig. 4d) showing that Pfs12 and Pfs38 proteins are anchored to merozoite membrane by GPI domains and Pfs41 interacts with these proteins to stabilize them. Pfs38 binds RBC surface via glycophorin A, while PfMSP-165, GLURP and SERA5 bind to the axis generated by Pfs41, Pfs12 and Pfs38.
Invasion inhibition assay (GIA)
The inhibitory potential of anti-Pfs38 antibodies on the invasion of Plasmodium merozoites into RBCs were evaluated. An invasion inhibition assay was performed on P. falciparum 3D7 using the purified anti-Pfs38 IgG at different concentrations. IgG purified from pre-immune sera served as a negative control. Anti-Pfs38 IgG showed an inhibition of approximately 30–40% at a concentration of 10 mg/mL (Fig. 4e).
Humoral immune responses to the proteins associated with Pfs38 protein complex
Irrespective of the differential reactivity, the relative high seroprevalence rates in both areas indicate that the 6-Cys proteins: Pfs38, Pfs12, Pfs41, and MSP-1 as well as SERA proteins used in the present study, are good immunogen and these proteins have adopted their natural folds. Taken together, these results indicate that proteins of the Pfs38 complex are expressed during the natural infection in geographical distinct parasite populations.
An effective blood-stage vaccine to prevent the prevalence of malaria or ameliorate the severity of disease is still a distant prospect because of major gaps in the knowledge of Plasmodium biology, especially in the understanding of molecular architecture of merozoite surface as well as the critical events involved in the invasion of RBCs. Among the many antigens that coat merozoite surface, 6-Cys proteins are of significant interest as they are expressed at multiple stages of P. falciparum life cycle and have a characteristic arrangement of cysteine residues [18, 29, 44–46]. Although 6-Cys domain proteins were identified more than 20 years ago, their functions at asexual blood stages are yet to be defined.
To get insights into the role of three 6-Cys proteins: Pfs41, Pfs38 and Pfs12, at asexual blood stages, particularly in the invasion process, these proteins were expressed and purified in E. coli expression systems and specific antibodies to these proteins were raised. These antibodies were specific as they recognized specific bands in asexual blood stages of P. falciparum lysates and stained the merozoite surface. It has been shown that Pfs12 and Pfs41 exist as heterodimer on the P. falciparum merozoite surface . To know whether these proteins are part of a large network, the P. falciparum schizont stage parasite lysate was immunoprecipitated using either anti-Pfs38 or anti-Pfs41 or anti-Pfs12 antibody and the immunoprecipitated samples were analysed by LC–MS/MS. A similar approach has been adopted by us and others to identify protein complexes in Plasmodium and other organisms . These analyses provided evidence for the association of three 6-cys proteins (Pfs38, Pfs12 and Pfs41) with other merozoite surface proteins: GLURP, PfMSP-1 and SERA-5 on the merozoite surface. Careful analysis of the peptides generated in MS/MS analysis showed that a region upstream of the PfMSP-119 is associated with the complex. Overall, these results suggested the existence of a large Pfs38 protein complex comprising of GLURP, SERA5, PfMSP-1, Pfs41, and Pfs12 proteins.
In vitro protein–protein interaction tools, such as ELISA based binding assays and Far western blot analysis between the six proteins of Pfs38 protein complex and co-localization studies, provided additional evidence for the existence of such a complex. The interaction between Pfs38 and GLURPR2 was further quantified by surface plasmon resonance (SPR) analysis in the present study. Although a couple of previous studies have shown an interaction between Pfs12/Pvs12 and Pfs41/Pvs41 [20, 40], other interactions between the components of Pfs38 complex have never been reported. Among the merozoite proteins identified in Pfs38 complex, Pfs12 and Pfs38 anchors to the merozoite membrane via GPI motif similar to several other merozoite surface proteins, while Pfs41, SERA5 and GLURP lack GPI-anchoring motifs and they interact with Pfs12 and Pfs38 via non-covalent interactions . Although MSP-1 has a GPI anchoring motif, nonetheless this protein undergoes processing and region(s) of MSP-1 that interacts with this complex are distant from PfMSP-119, a region anchored to the merozoite membrane .
Gene knock-out studies have shown that neither Pfs12 nor Pfs41 are essential for the malaria parasite growth or invasion and antibodies to these antigens do not significantly block erythrocyte invasion in vitro . These proteins also did not show binding to human erythrocyte in an in vitro assay . As the structural and biochemical characteristics of 6-Cys proteins predict their role(s) in the process of recognition and adhesion of host cells [26, 29], the possibility of Pfs38, Pfs41 and Pfs12 interaction with human RBCs was explored. As shown previously, Pfs41 and Pfs12 did not show binding to human erythrocytes, however, Pfs38 bound to RBCs via glycophorin A and anti-Pfs38 antibodies showed a moderate invasion (~40%) inhibition activity. These results are in line with a previous study where anti-Pfs38 antibody generated against a plant-produced recombinant Pfs38 showed inhibition of ≥60% . Although a moderate level of invasion inhibition was observed with anti-Pfs38 antibody, it is possible that for greater protection antibodies to other components of the complex may also be required. This is evident in an earlier report that showed better protection against a Plasmodium yoelii challenge in mice immunized with PfAMA-1-RON2 complex in comparison to the mice immunized with each antigen alone . Together these studies advocate the development of a sub-unit malaria vaccine based on the candidates that are present in complexes with one or more binding partners instead of the individual component.
To explore whether the recombinant proteins used in interaction analysis were properly folded with intact conformational epitopes and are targets for naturally acquired humoral immunity, these six antigens of Pfs38 protein complex were screened against plasma from 28 Liberian and 28 P. falciparum-infected Indian patients. All the six antigens: Pfs38, Pfs12, Pfs41, PfMSP-165, GLURPR2, and SERA5 showed at least a two-fold change in IgG reactivity between the naïve sera and P. falciparum-exposed plasma in two geographically distinct populations. However, antibody responses among six antigens varied. GLURP R2 and PfMSP-165 showed significantly high antibodies than members of the 6-Cys family. Similar high responses have been observed against GLURPR2 in a number of previous studies [33, 51, 52]. Differences in the humoral responses against these antigens between the Liberian and Indian sera were observed. The difference in the reactivity observed between Indian and Liberian sera may be because Liberia is a malaria-endemic region, while Indian isolates were from non-endemic areas. Interestingly denaturing four of these antigens by urea treatment significantly reduced their reactivity with Liberian sera thereby further confirming the folding of recombinant proteins used in the present study.
In summary, the existence of a large Pfs38 complex on P. falciparum merozoites consisting of three 6-Cys family members: Pfs38, Pfs41 and Pfs12 that associate with GLURP, PfMSP-165 and SERA5 was revealed. Pfs38 protein of this large Pfs38 complex binds to RBC via glycophorin A. Two proteins of this complex: GLURP and PfMSP-165 showed high seroreactivity to sera from P. falciparum-infected patients with a seroprevalence of >90% from two geographically distinct populations. Although broader epidemiological investigations and in vivo challenge studies are required, the results of the present study point towards developing malaria sub-unit vaccines based on merozoite surface protein complexes.
GP, AD, IK, SR, and SD performed research experiments; AP, SKS and MT contributed tools; GP and PM designed the study, interpreted data and wrote manuscript; AM and MT contributed to experiment design, data interpretation and manuscript preparation. All authors read and approved the final manuscript.
GP acknowledges the financial support from Department of Biotechnology, Government of India in the form of DBT-JRF Fellowship. We thank Rotary blood bank, for providing human red blood cells. We thank Dr. Brendan Crabb for SERA5 expression clone and Prof V.S Chauhan as well as Punit for providing PfMSP-119 protein and anti-PfMSP-119 antibody. We also thank Dr. Renu Tuteja for providing PfMLH protein.
The authors declare that they have no competing interests.
Availability of data and materials
All data generated or analysed during this study are included in this published article (and its supplementary information files).
Ethical approval and consent to participate
All animal experiments conducted were approved by the Institutional Animals Ethics Committee of ICGEB (IAEC-ICGEB) under the approval no ICGEB/AH/2015/01/MAL-74. Written informed consents were obtained from patients for all Indian sera samples. Liberian and Danish sera samples are collection of Dr. Michael Theisen of Statens Serum Institut.
The study was supported by Department of Biotechnology, Government of India (BT/01/CEIB/11/V/01, BT/PR5267/MED/15/87/2012 and BT/IN/Denmark/13/SS/2013 supervised by PM and AM). The funders had no role in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- WHO. World malaria report. Geneva: World Health Organization; 2015. http://www.who.int/malaria/publications/world-malaria-report-2015/report/en/.
- Bledsoe GH. Malaria primer for clinicians in the United States. South Med J. 2005;98:1197–204.View ArticlePubMedGoogle Scholar
- Ogutu BR, Apollo OJ, McKinney D, Okoth W, Siangla J, Dubovsky F, et al. Blood stage malaria vaccine eliciting high antigen-specific antibody concentrations confers no protection to young children in Western Kenya. PLoS ONE. 2009;4:e4708.View ArticlePubMedPubMed CentralGoogle Scholar
- Sagara I, Dicko A, Ellis RD, Fay MP, Diawara SI, Assadou MH, et al. A randomized controlled phase 2 trial of the blood stage AMA1-C1/Alhydrogel malaria vaccine in children in Mali. Vaccine. 2009;27:3090–8.View ArticlePubMedPubMed CentralGoogle Scholar
- Genton B, Betuela I, Felger I, Al-Yaman F, Anders RF, Saul A, et al. A recombinant blood-stage malaria vaccine reduces Plasmodium falciparum density and exerts selective pressure on parasite populations in a phase 1-2b trial in Papua New Guinea. J Infect Dis. 2002;185:820–7.View ArticlePubMedGoogle Scholar
- Thera MA, Doumbo OK, Coulibaly D, Laurens MB, Ouattara A, Kone AK, et al. A field trial to assess a blood-stage malaria vaccine. N Engl J Med. 2011;365:1004–13.View ArticlePubMedPubMed CentralGoogle Scholar
- von Bohl A, Kuehn A, Simon N, Ngongang VN, Spehr M, Baumeister S, et al. A WD40-repeat protein unique to malaria parasites associates with adhesion protein complexes and is crucial for blood stage progeny. Malar J. 2015;14:435.View ArticleGoogle Scholar
- Kadekoppala M, Holder AA. Merozoite surface proteins of the malaria parasite: the MSP1 complex and the MSP7 family. Int J Parasitol. 2010;40:1155–61.View ArticlePubMedGoogle Scholar
- Richard D, MacRaild CA, Riglar DT, Chan JA, Foley M, Baum J, et al. Interaction between Plasmodium falciparum apical membrane antigen 1 and the rhoptry neck protein complex defines a key step in the erythrocyte invasion process of malaria parasites. J Biol Chem. 2010;285:14815–22.View ArticlePubMedPubMed CentralGoogle Scholar
- Lin CS, Uboldi AD, Epp C, Bujard H, Tsuboi T, Czabotar PE, et al. Multiple P. falciparum merozoite surface protein 1 complexes mediate merozoite binding to human erythrocytes. J Biol Chem. 2016;291:7703–15.View ArticlePubMedGoogle Scholar
- Kauth CW, Epp C, Bujard H, Lutz R. The merozoite surface protein 1 complex of human malaria parasite Plasmodium falciparum: interactions and arrangements of subunits. J Biol Chem. 2003;278:22257–64.View ArticlePubMedGoogle Scholar
- Cao J, Kaneko O, Thongkukiatkul A, Tachibana M, Otsuki H, Gao Q, et al. Rhoptry neck protein RON2 forms a complex with microneme protein AMA1 in Plasmodium falciparum merozoites. Parasitol Int. 2009;58:29–35.View ArticlePubMedGoogle Scholar
- Cowman AF, Berry D, Baum J. The cellular and molecular basis for malaria parasite invasion of the human red blood cell. J Cell Biol. 2012;198:961–71.View ArticlePubMedPubMed CentralGoogle Scholar
- Ishino T, Chinzei Y, Yuda M. Two proteins with 6-cys motifs are required for malarial parasites to commit to infection of the hepatocyte. Mol Microbiol. 2005;58:1264–75.View ArticlePubMedGoogle Scholar
- van Dijk MR, van Schaijk BC, Khan SM, van Dooren MW, Ramesar J, Kaczanowski S, et al. Three members of the 6-cys protein family of Plasmodium play a role in gamete fertility. PLoS Pathog. 2010;6:e1000853.View ArticlePubMedPubMed CentralGoogle Scholar
- Templeton TJ, Kaslow DC. Identification of additional members define a Plasmodium falciparum gene superfamily which includes Pfs48/45 and Pfs230. Mol Biochem Parasitol. 1999;101:223–7.View ArticlePubMedGoogle Scholar
- Sanders PR, Gilson PR, Cantin GT, Greenbaum DC, Nebl T, Carucci DJ, et al. Distinct protein classes including novel merozoite surface antigens in Raft-like membranes of Plasmodium falciparum. J Biol Chem. 2005;280:40169–76.View ArticlePubMedGoogle Scholar
- Gerloff DL, Creasey A, Maslau S, Carter R. Structural models for the protein family characterized by gamete surface protein Pfs230 of Plasmodium falciparum. Proc Natl Acad Sci USA. 2005;102:13598–603.View ArticlePubMedPubMed CentralGoogle Scholar
- Carter R, Coulson A, Bhatti S, Taylor BJ, Elliott JF. Predicted disulfide-bonded structures for three uniquely related proteins of Plasmodium falciparum, Pfs230, Pfs48/45 and Pf12. Mol Biochem Parasitol. 1995;71:203–10.View ArticlePubMedGoogle Scholar
- Taechalertpaisarn T, Crosnier C, Bartholdson SJ, Hodder AN, Thompson J, Bustamante LY, et al. Biochemical and functional analysis of two Plasmodium falciparum blood-stage 6-cys proteins: P12 and P41. PLoS ONE. 2012;7:e41937.View ArticlePubMedPubMed CentralGoogle Scholar
- van Dijk MR, Douradinha B, Franke-Fayard B, Heussler V, van Dooren MW, van Schaijk B, et al. Genetically attenuated, P36p-deficient malarial sporozoites induce protective immunity and apoptosis of infected liver cells. Proc Natl Acad Sci USA. 2005;102:12194–9.View ArticlePubMedPubMed CentralGoogle Scholar
- Waters A. Malaria: new vaccines for old? Cell. 2006;124:689–93.View ArticlePubMedGoogle Scholar
- VanBuskirk KM, O’Neill MT, De La Vega P, Maier AG, Krzych U, Williams J, et al. Preerythrocytic, live-attenuated Plasmodium falciparum vaccine candidates by design. Proc Natl Acad Sci USA. 2009;106:13004–9.View ArticlePubMedPubMed CentralGoogle Scholar
- Kumar N. Target antigens of malaria transmission blocking immunity exist as a stable membrane bound complex. Parasite Immunol. 1987;9:321–35.View ArticlePubMedGoogle Scholar
- van Dijk MR, Janse CJ, Thompson J, Waters AP, Braks JA, Dodemont HJ, et al. A central role for P48/45 in malaria parasite male gamete fertility. Cell. 2001;104:153–64.View ArticlePubMedGoogle Scholar
- Williamson KC. Pfs230: from malaria transmission-blocking vaccine candidate toward function. Parasite Immunol. 2003;25:351–9.View ArticlePubMedGoogle Scholar
- Read D, Lensen AH, Begarnie S, Haley S, Raza A, Carter R. Transmission-blocking antibodies against multiple, non-variant target epitopes of the Plasmodium falciparum gamete surface antigen Pfs230 are all complement-fixing. Parasite Immunol. 1994;16:511–9.View ArticlePubMedGoogle Scholar
- Quakyi IA, Carter R, Rener J, Kumar N, Good MF, Miller LH. The 230-kDa gamete surface protein of Plasmodium falciparum is also a target for transmission-blocking antibodies. J Immunol. 1987;139:4213–7.PubMedGoogle Scholar
- Tonkin ML, Arredondo SA, Loveless BC, Serpa JJ, Makepeace KA, Sundar N, et al. Structural and biochemical characterization of Plasmodium falciparum 12 (Pf12) reveals a unique interdomain organization and the potential for an antiparallel arrangement with Pf41. J Biol Chem. 2013;288:12805–17.View ArticlePubMedPubMed CentralGoogle Scholar
- Kennedy AT, Schmidt CQ, Thompson JK, Weiss GE, Taechalertpaisarn T, Gilson PR, et al. Recruitment of factor H as a novel complement evasion strategy for blood-stage Plasmodium falciparum infection. J Immunol. 2016;196:1239–48.View ArticlePubMedGoogle Scholar
- Trager W, Jensen JB. Human malaria parasites in continuous culture. Science. 1976;193:673–5.View ArticlePubMedGoogle Scholar
- Lambros C, Vanderberg JP. Synchronization of Plasmodium falciparum erythrocytic stages in culture. J Parasitol. 1979;65:418–20.View ArticlePubMedGoogle Scholar
- Theisen M, Vuust J, Gottschau A, Jepsen S, Hogh B. Antigenicity and immunogenicity of recombinant glutamate-rich protein of Plasmodium falciparum expressed in Escherichia coli. Clin Diagn Lab Immunol. 1995;2:30–4.PubMedPubMed CentralGoogle Scholar
- Kanodia S, Kumar G, Rizzi L, Pedretti A, Hodder AN, Romeo S, et al. Synthetic peptides derived from the C-terminal 6 kDa region of Plasmodium falciparum SERA5 inhibit the enzyme activity and malaria parasite development. Biochim Biophys Acta. 2014;1840:2765–75.View ArticlePubMedGoogle Scholar
- Ko YP, Liang X, Smith CW, Degen JL, Hook M. Binding of Efb from Staphylococcus aureus to fibrinogen blocks neutrophil adherence. J Biol Chem. 2011;286:9865–74.View ArticlePubMedPubMed CentralGoogle Scholar
- Wu Y, Li Q, Chen XZ. Detecting protein–protein interactions by Far western blotting. Nat Protoc. 2007;2:3278–84.View ArticlePubMedGoogle Scholar
- Wickramarachchi T, Devi YS, Mohmmed A, Chauhan VS. Identification and characterization of a novel Plasmodium falciparum merozoite apical protein involved in erythrocyte binding and invasion. PLoS ONE. 2008;3:e1732.View ArticlePubMedPubMed CentralGoogle Scholar
- Courtin D, Oesterholt M, Huismans H, Kusi K, Milet J, Badaut C, et al. The quantity and quality of African children’s IgG responses to merozoite surface antigens reflect protection against Plasmodium falciparum malaria. PLoS ONE. 2009;4:e7590.View ArticlePubMedPubMed CentralGoogle Scholar
- Tarique M, Satsangi AT, Ahmad M, Singh S, Tuteja R. Plasmodium falciparum MLH is schizont stage specific endonuclease. Mol Biochem Parasitol. 2012;181:153–61.View ArticlePubMedGoogle Scholar
- Singh S, Pandey K, Chattopadhayay R, Yazdani SS, Lynn A, Bharadwaj A, et al. Biochemical, biophysical, and functional characterization of bacterially expressed and refolded receptor binding domain of Plasmodium vivax duffy-binding protein. J Biol Chem. 2001;276:17111–6.View ArticlePubMedGoogle Scholar
- Ramasamy G, Gupta D, Mohmmed A, Chauhan VS. Characterization and localization of Plasmodium falciparum homolog of prokaryotic ClpQ/HslV protease. Mol Biochem Parasitol. 2007;152:139–48.View ArticlePubMedGoogle Scholar
- Garcia J, Curtidor H, Pinzon CG, Vanegas M, Moreno A, Patarroyo ME. Identification of conserved erythrocyte binding regions in members of the Plasmodium falciparum Cys6 lipid raft-associated protein family. Vaccine. 2009;27:3953–62.View ArticlePubMedGoogle Scholar
- Baldwin MR, Li X, Hanada T, Liu SC, Chishti AH. Merozoite surface protein 1 recognition of host glycophorin A mediates malaria parasite invasion of red blood cells. Blood. 2015;125:2704–11.View ArticlePubMedPubMed CentralGoogle Scholar
- Williamson KC, Keister DB, Muratova O, Kaslow DC. Recombinant Pfs230, a Plasmodium falciparum gametocyte protein, induces antisera that reduce the infectivity of Plasmodium falciparum to mosquitoes. Mol Biochem Parasitol. 1995;75:33–42.View ArticlePubMedGoogle Scholar
- Arredondo SA, Cai M, Takayama Y, MacDonald NJ, Anderson DE, Aravind L, et al. Structure of the Plasmodium 6-cysteine s48/45 domain. Proc Natl Acad Sci USA. 2012;109:6692–7.View ArticlePubMedPubMed CentralGoogle Scholar
- Hostetler JB, Sharma S, Bartholdson SJ, Wright GJ, Fairhurst RM, Rayner JC. A library of Plasmodium vivax recombinant merozoite proteins reveals new vaccine candidates and protein-protein interactions. PLoS Negl Trop Dis. 2015;9:e0004264.View ArticlePubMedPubMed CentralGoogle Scholar
- Ranjan R, Chugh M, Kumar S, Singh S, Kanodia S, Hossain MJ, et al. Proteome analysis reveals a large merozoite surface protein-1 associated complex on the Plasmodium falciparum merozoite surface. J Proteom Res. 2011;10:680–91.View ArticleGoogle Scholar
- Li G, Basagoudanavar SH, Gowda DC. Effect of GPI anchor moiety on the immunogenicity of DNA plasmids encoding the 19-kDa C-terminal portion of Plasmodium falciparum MSP-1. Parasite Immunol. 2008;30:315–22.View ArticlePubMedPubMed CentralGoogle Scholar
- Feller T, Thom P, Koch N, Spiegel H, Addai-Mensah O, Fischer R, et al. Plant-based production of recombinant Plasmodium surface protein pf38 and evaluation of its potential as a vaccine candidate. PLoS ONE. 2013;8:e79920.View ArticlePubMedPubMed CentralGoogle Scholar
- Srinivasan P, Ekanem E, Diouf A, Tonkin ML, Miura K, Boulanger MJ, et al. Immunization with a functional protein complex required for erythrocyte invasion protects against lethal malaria. Proc Natl Acad Sci USA. 2014;111:10311–6.View ArticlePubMedPubMed CentralGoogle Scholar
- Dziegiel M, Borre MB, Jepsen S, Hogh B, Petersen E, Vuust J. Recombinant Plasmodium falciparum glutamate rich protein; purification and use in enzyme-linked immunosorbent assay. Am J Trop Med Hyg. 1991;44:306–13.PubMedGoogle Scholar
- Dziegiel M, Rowe P, Bennett S, Allen SJ, Olerup O, Gottschau A, et al. Immunoglobulin M and G antibody responses to Plasmodium falciparum glutamate-rich protein: correlation with clinical immunity in Gambian children. Infect Immun. 1993;61:103–8.PubMedPubMed CentralGoogle Scholar